Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Apr 20;16(4):203–210. [Article in Chinese] doi: 10.3779/j.issn.1009-3419.2013.04.06

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

版权所有©《中国肺癌杂志》编辑部2013

Copyright ©2013 Chinese Journal of Lung Cancer. All rights reserved.

This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/

PMC Copyright notice

66例入组的EGFR突变型NSCLC患者的成本效益分析模型。包括两种治疗方法所使用的药物吉非替尼和厄洛替尼, 以及处理相关治疗副反应。

The cost-effectiveness analysis model of 66 EGFR mutant NSCLC patients, including two therapeutic drugs gefitinib and erlotinib, and the treatment of adverse effect.EGFR:epidermal growth factor receptor.NSCLC:non-small cell lung cancer; EGFR:epidermal growth factor receptor.